AVTX · Categories · Coverage
AVTX - Analyst coverage initiated
Avalo Therapeutics Inc. (AVTX) analyst coverage initiated - real-time wire coverage filtered to Coverage only.
Recent Coverage for AVTX
- Wolfe Research initiated coverage on Avalo Therapeutics with a new price targetWolfe Research initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $48.00
- Citizens initiated coverage on Avalo Therapeutics with a new price targetCitizens initiated coverage of Avalo Therapeutics with a rating of Mkt Outperform and set a new price target of $52.00
- Guggenheim initiated coverage on Avalo Therapeutics with a new price targetGuggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00
- Mizuho initiated coverage on Avalo Therapeutics with a new price targetMizuho initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $39.00
- TD Cowen initiated coverage on Avalo TherapeuticsTD Cowen initiated coverage of Avalo Therapeutics with a rating of Buy
- Cantor Fitzgerald initiated coverage on Avalo TherapeuticsCantor Fitzgerald initiated coverage of Avalo Therapeutics with a rating of Overweight
- Stifel initiated coverage on Avalo Therapeutics with a new price targetStifel initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $36.00
- Jefferies initiated coverage on Avalo Therapeutics with a new price targetJefferies initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $23.00
- Piper Sandler initiated coverage on Avalo Therapeutics with a new price targetPiper Sandler initiated coverage of Avalo Therapeutics with a rating of Overweight and set a new price target of $48.00
- Wedbush initiated coverage on Avalo Therapeutics with a new price targetWedbush initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $18.00
- BTIG Research initiated coverage on Avalo Therapeutics with a new price targetBTIG Research initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $40.00
- H.C. Wainwright initiated coverage on Avalo TherapeuticsH.C. Wainwright initiated coverage of Avalo Therapeutics with a rating of Neutral
- RBC Capital Mkts initiated coverage on Avalo Therapeutics with a new price targetRBC Capital Mkts initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $6.00